Edition:
United Kingdom

Julie Steenhuysen

Novavax lays out specific minority targets for U.S. COVID-19 vaccine trial

30 Oct 2020

CHICAGO Novavax Inc on Friday outlined specific diversity targets for its large-scale COVID-19 vaccine study expected to begin in the United States and Mexico next month.

Fauci says first U.S. COVID-19 vaccines could ship late December or early January

30 Oct 2020

CHICAGO If all goes well, the first doses of a safe and effective coronavirus vaccine will likely become available to some high-risk Americans in late December or early January, Dr. Anthony Fauci, the top U.S. infectious diseases expert, said on Thursday. | Video

Fauci says first U.S. COVID-19 vaccines could ship late December or early January

29 Oct 2020

CHICAGO If all goes well, the first doses of a safe and effective coronavirus vaccine will likely become available to some high-risk Americans in late December or early January, Dr. Anthony Fauci, the top U.S. infectious diseases expert, said on Thursday.

Next crop of COVID-19 vaccine developers take more traditional route

29 Oct 2020

CHICAGO/BERLIN The handful of drugmakers dominating the global coronavirus vaccine race are pushing the boundaries of vaccine technology. The next crop under development feature more conventional, proven designs.

Novavax delays U.S. trial of COVID-19 vaccine to November

27 Oct 2020

Novavax Inc on Tuesday delayed the start of a late-stage U.S. trial of its experimental coronavirus vaccine by roughly a month to the end of November, citing delays in scaling up the manufacturing process.

AstraZeneca resumes U.S. COVID-19 vaccine trial and next week J&J prepares to do same

24 Oct 2020

AstraZeneca Plc has resumed the U.S. trial of its experimental COVID-19 vaccine after approval by regulators, and Johnson & Johnson is preparing to resume its trial on Monday or Tuesday, the companies said on Friday. | Video

Exclusive: U.S. trial of AstraZeneca COVID-19 vaccine may resume this week - sources

21 Oct 2020

CHICAGO/WASHINGTON AstraZeneca Plc's COVID-19 vaccine trial in the United States is expected to resume as early as this week after the U.S. Food and Drug Administration completed its review of a serious illness in a study participant, four sources told Reuters.

World News